newsfilter
← Latest News
Business Wire·

The Medicines Company Announces 5th Review of Un-blinded Data and Recommendation by Independent Data Monitoring Committee to Continue Inclisiran Phase 3 Trials

PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) today announced that the 5th review of un-blinded safety and efficacy data by the Independent Data Monitoring Committee (IDMC) for inclisiran Phase 3 trials has been completed. The IDMC has once again recommended that the trials continue as designed and conducted, without modification.